Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$27.06 +0.2%	$28.25	$23.23 ▼ $42.29	$869.49M	0.76	442,325 shs	310,177 shs
ELVN Enliven Therapeutics	$19.85 +4.8%	$19.19	$13.30 ▼ $30.03	$972.73M	1.03	260,886 shs	216,036 shs
NVCT Nuvectis Pharma	$9.62 -3.4%	$8.69	$4.44 ▼ $11.80	$225.03M	-0.11	126,047 shs	106,889 shs
XFOR X4 Pharmaceuticals	$3.75 -13.0%	$8.06	$3.74 ▼ $36.00	$651.23M	0.58	91,937 shs	263,792 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	-2.17%	+3.89%	-9.55%	-16.95%	-26.89%
ELVN Enliven Therapeutics	+1.55%	+6.58%	-3.76%	-10.95%	+8.91%
NVCT Nuvectis Pharma	-3.58%	-4.32%	+1.94%	+47.77%	+63.82%
XFOR X4 Pharmaceuticals	-0.92%	-28.63%	-39.23%	-78.30%	-87.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.0398 of 5 stars	3.4	1.0	3.0	2.8	0.8	2.5
ELVN Enliven Therapeutics	2.2596 of 5 stars	3.6	0.0	0.0	2.9	4.2	0.0
NVCT Nuvectis Pharma	2.6006 of 5 stars	3.5	0.0	0.0	2.3	5.0	0.6
XFOR X4 Pharmaceuticals	3.8492 of 5 stars	3.5	2.0	4.6	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.60	61.12% Upside
ELVN Enliven Therapeutics	3.25	Buy	$40.33	103.19% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	76.72% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$85.00	2,166.67% Upside

Current Analyst Ratings Breakdown

Latest NVCT, XFOR, ELVN, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $15.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/2/2025	NVCT Nuvectis Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
3/27/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
3/26/2025	XFOR X4 Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00
3/17/2025	NVCT Nuvectis Pharma	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
2/25/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $11.00
2/7/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
2/4/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$37.00 ➝ $36.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.38	$9.80 per share	2.76	$5.99 per share	4.52
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A
XFOR X4 Pharmaceuticals	$2.56M	254.69	N/A	N/A	$0.31 per share	12.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$48.15M	$1.86	11.66	4.50	N/A	14.78%	104.67%	18.38%	5/8/2025 (Estimated)
ELVN Enliven Therapeutics	-$71.58M	-$1.89	N/A	N/A	N/A	N/A	-29.46%	-27.33%	5/13/2025 (Estimated)
NVCT Nuvectis Pharma	-$22.26M	-$1.11	N/A	N/A	N/A	N/A	-155.80%	-104.02%	5/6/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$101.17M	-$0.19	N/A	N/A	N/A	N/A	-236.19%	-75.14%	5/1/2025 (Estimated)

Latest NVCT, XFOR, ELVN, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	N/A	N/A	N/A	$174.96 million	N/A
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$4.13	$0.04	+$4.17	$0.04	$7.03 million	$28.81 million
3/25/2025	Q4 2024	XFOR X4 Pharmaceuticals	-$5.10	-$6.00	-$0.90	-$0.20	$1.07 million	$1.43 million
3/13/2025	Q4 2024	ELVN Enliven Therapeutics	-$0.53	-$0.46	+$0.07	-$0.46	N/A	$0.03 million
3/4/2025	Q4 2024	NVCT Nuvectis Pharma	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.43	0.97	0.88
ELVN Enliven Therapeutics	N/A	17.44	17.44
NVCT Nuvectis Pharma	N/A	2.74	2.74
XFOR X4 Pharmaceuticals	1.26	4.89	4.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
ELVN Enliven Therapeutics	95.08%
NVCT Nuvectis Pharma	96.77%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
ELVN Enliven Therapeutics	29.20%
NVCT Nuvectis Pharma	35.78%
XFOR X4 Pharmaceuticals	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
ELVN Enliven Therapeutics	50	49.00 million	34.59 million	Optionable
NVCT Nuvectis Pharma	8	23.39 million	12.41 million	Not Optionable
XFOR X4 Pharmaceuticals	80	173.66 million	167.78 million	Optionable

NVCT, XFOR, ELVN, and COLL Headlines

Recent News About These Companies

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4.9% - Time to Sell?

May 1 at 1:38 PM | marketbeat.com

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1 at 1:13 PM | seekingalpha.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1 at 9:20 AM | finance.yahoo.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1 at 6:01 AM | globenewswire.com

X4 Pharmaceuticals Q1 2025 Earnings Preview

April 30 at 6:15 PM | msn.com

X4 Pharmaceuticals Analyst Ratings

April 30 at 6:15 PM | benzinga.com

Earnings Preview For X4 Pharmaceuticals

April 30 at 6:15 PM | benzinga.com

X4 Pharmaceuticals (NASDAQ:XFOR) Sets New 1-Year Low - Here's Why

April 30 at 10:00 AM | marketbeat.com

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

April 30 at 7:41 AM | insidermonkey.com

X4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28

April 26, 2025 | nasdaq.com

X4 Pharmaceuticals trading halted, news pending

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals announces 1-for-30 reverse stock split

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals to conduct reverse stock split

April 24, 2025 | msn.com

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

April 24, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Reverse Stock Split

April 24, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 23, 2025 | globenewswire.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript

March 29, 2025 | msn.com

XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25…

March 27, 2025 | finance.yahoo.com

Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views

March 27, 2025 | benzinga.com

X4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last year

March 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixafor

March 25, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, XFOR, ELVN, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$27.06 +0.06 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$25.11 -1.95 (-7.20%)

As of 04:23 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$19.85 +0.91 (+4.80%)

Closing price 04:00 PM Eastern

Extended Trading

$19.86 +0.01 (+0.08%)

As of 04:20 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Nuvectis Pharma NASDAQ:NVCT

$9.62 -0.34 (-3.41%)

Closing price 04:00 PM Eastern

Extended Trading

$9.62 0.00 (0.00%)

As of 05:48 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

X4 Pharmaceuticals NASDAQ:XFOR

$3.75 -0.56 (-12.99%)

Closing price 04:00 PM Eastern

Extended Trading

$3.84 +0.09 (+2.40%)

As of 07:59 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time